New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For NDAQ;AAPL;BBRY;HD;GOOG;REGN;SNY;NVO;HEK;GMCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>
March 26, 2015
07:25 EDTGOOGThe Economist to hold a forum
Subscribe for More Information
07:21 EDTAAPLApple price target raised to $145 from $140 at Credit Suisse
Credit Suisse raised Outperform rated Apple's price target to $145 and increased estimates based on near-term iPhone strength, better mix, and Watch awareness, all of which should offset currency headwinds.
06:59 EDTGOOGFacebook video outpaces YouTube in recent metrics, BI says
Subscribe for More Information
06:58 EDTAAPLApple may introduce trade-in program for iPhones in China, Bloomberg reports
Apple plans to launch a trade-in program for iPhones in China with FoxConn Technology, reports Bloomberg. According to people familiar with the effort, consumers will be able to take older iPhones to Apple stores for credit against the company's products as soon as March 31. Foxconn will buy and re-sell the phones as part of the program. Reference Link
06:55 EDTBBRYBlackBerry revenue likely to bottom in Q4, says JPMorgan
Subscribe for More Information
06:41 EDTGOOGTwitter to outpace Yahoo in display ad revenue, WSJ says
Subscribe for More Information
06:05 EDTGOOGIntel to partner with notebook makers for Chromebook 2-in-1s, DigiTimes says
Subscribe for More Information
05:59 EDTAAPLApple Watch yields low but are increasing, DigiTimes reports
Apple Watch yields in Q1 are reportedly mostly below 50%, but supply chain makers have noted the yields are on the rise, reports DigiTimes. Total shipments are for the device during 2015 are expected to reach 15M after an initial 4M shipments in Q1. Due to low yields in assembly and overall production , makers estimate the device will see an initial 2-2.2M in shipments before its release in April. Reference Link
05:58 EDTBBRYStocks with implied volatility above IV index mean; AMZN BBRY
Subscribe for More Information
05:58 EDTAAPLApple expected to release 3 new iPhone models in 2H15, DigiTimes reports
Subscribe for More Information
05:56 EDTAAPLTSMC to supply chips for rumored iPhone 6S and 6C models, DigiTimes reports
TSMC (TSM) will remain the major processor supplier for Apple (AAPL) in 2H15, reports DigiTimes. According to industry sources, TSMC will supply 20nm chips for the upcoming 6S and 6C models. TSMC is reportedly the sole supplier of processors for Apple's iPhone 6 and 6 Plus. Reference Link
05:29 EDTSNYGenzyme reports Cerdelga data shows effectiveness in treating Gaucher disease
Genzyme, a Sanofi company, announced the publication of results from the ENCORE study exploring Cerdelga as a maintenance therapy suitable for adult patients who had reached pre-specific treatment goals on enzyme replacement therapy, or ERT, in the March 26 online issue of The Lancet. ENCORE is a randomized, multinational, Phase 3, open-label, non-inferiority study designed to determine whether patients with Gaucher disease type 1 who had been stabilized after 3 or more years of ERT infusions would remain stable after switching to Cerdelga, a novel, oral, selective inhibitor of glucosylceramide synthase. Eligible patients were randomized 2:1 to receive either oral Cerdelga or ERT with Cerezyme over a period of 12 months. The composite primary efficacy endpoint was the percentage of patients whose hematologic parameters and organ volumes remained stable, using the following stability criteria established for patients with Gaucher disease type 1 on maintenance therapy with Cerezyme: Hemoglobin concentration that did not decrease more than 1.5 g/dL; Platelet count that did not decrease more than 25%; Spleen volume that did not increase more than 25%; Liver volume that did not increase more than 20%. After 12 months, 85% of patients receiving Cerdelga and 94% of patients receiving Cerezyme met the composite endpoint of stability in all four of these measures. The difference between the two treatments was within the pre-specified margins. The principal secondary endpoints were stability with respect to the individual components of the primary endpoint. At least 93% of Cerdelga patients remained stable with respect to hemoglobin concentration, platelet count, spleen volume, and liver volume after 12 months of treatment. Additional endpoints evaluated bone disease, Gaucher disease severity, quality-of-life and Gaucher-disease associated biomarkers.
March 25, 2015
19:21 EDTAAPLApple, Beats working on streaming music service to rival Spotify, NY Times says
Apple (AAPL) is working with Beats to introduce a subscription streaming service to compete directly with services such as Spotify, according to the New York Times, citing people briefed on the company’s plans. Additionally, Apple is expected to overhaul iTunes Radio, the free service that competes with Pandora (P), the Times added. Reference Link
16:00 EDTAAPLOptions Update; March 25, 2015
Subscribe for More Information
13:22 EDTNVONovo Nordisk says 3a trials achieved primary objectives
Novo Nordisk announced headline results from the final phase 3a trials for faster-acting insulin aspart, onset 1 and onset 2. The trials investigated the efficacy and safety of faster-acting insulin aspart compared with NovoRapid in a basal-bolus regimen in people with type 1 and type 2 diabetes, respectively. Both trials achieved their primary objectives by demonstrating that treatment with faster-acting insulin aspart is non-inferior to NovoRapid with regard to lowering of HbA1c. For people with type 1 diabetes, the HbA1c lowering achieved with faster-acting insulin aspart was statistically significantly larger than that achieved with NovoRapid when the insulins were given at mealtime. In addition, treatment with faster-acting insulin aspart was associated with less increase of postprandial glucose than NovoRapid during meal tests in both trials. In both trials, the previously reported safety and tolerability profiles of faster-acting insulin aspart and NovoRapid were confirmed, and there were no apparent differences between the two treatment groups with respect to adverse events and other safety parameters, Novo said.
12:17 EDTSNYSanofi Pasteur announces FDA approval of Quadracel DTaP-IPV vaccine
Subscribe for More Information
11:03 EDTREGNRegeneron confirms FDA approval of EYLEA
Subscribe for More Information
10:35 EDTREGNFDA approves expanded indication for Eylea
Subscribe for More Information
10:03 EDTNVOHigh option volume stocks
High option volume stocks: NVO SXC SONC EXH KRFT WLB ETR LXK APOL EWH
09:45 EDTAAPLApple to complete R&D facility in Yokohoma, Japan in 2016, Apple Insider reports
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use